SCHEMBL10023943

SCHEMBL10023943

C=CCC(CC)(CC=C)C(=O)OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.50
CYP4A11 Q02928 2/20 0.50
PKM P14618 3/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 2/20 0.34
HSD17B10 Q99714 1/20 0.34
THRB P10828 2/20 0.34
ALOX15 P16050 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
HTT P42858 1/20 0.33
MAPK1 P28482 1/20 0.33
SOAT1 P35610 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16150101 0.96 CYP4F2 (0.50) CYP4F2CYP4A11PKMALDH1A1KDM4E
SCHEMBL1361264 0.92 CYP4F2 (0.44) CYP4F2CYP4A11PKMALDH1A1KDM4E
SCHEMBL15070911 0.88 CYP4F2 (0.47) CYP4F2CYP4A11PKMALDH1A1KDM4E
SCHEMBL1361266 0.86 TSHR (0.41) CYP4F2CYP4A11ALDH1A1HSD17B10THRB
SCHEMBL10118792 0.86 CYP4F2 (0.42) CYP4F2CYP4A11PKMALDH1A1KDM4E
SCHEMBL15070913 0.86 CYP4F2 (0.54) CYP4F2CYP4A11PKMALDH1A1MEN1
SCHEMBL27681347 0.86 CYP4F2 (0.54) CYP4F2CYP4A11PKMALDH1A1KDM4E
SCHEMBL23132525 0.83 CYP4F2 (0.42) CYP4F2CYP4A11PKMALDH1A1KDM4E
SCHEMBL6910898 0.83 CYP4F2 (0.39) CYP4F2CYP4A11PKMALDH1A1KDM4E
SCHEMBL10136665 0.82 CYP4F2 (0.38) CYP4F2CYP4A11PKMALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11794179-B2 Synthesis and characterization of metathesis catalysts UMICORE AG & CO. KG 2023-10-24 US disclosed
US-11779912-B2 Synthesis and characterization of Ru alkylidene complexes UMICORE AG & CO. KG (DE) 2023-10-10 US disclosed
US-20230151128-A1 NEAR INFRARED (NIR) LIGHT CONTROLLED RUTHENIUM CATALYZED OLEFIN METATHESIS NATIONAL SCIENCE FOUNDATION 2023-05-18 US disclosed
US-9988339-B2 Nonpolar phase-soluble metathesis catalysts THE TEXAS A&M UNIVERSITY SYSTEM (US) 2018-06-05 US disclosed
US-9920086-B2 Ruthenium-based complexes, their preparation and use as catalysts ARLANXEO DE GMBH (DE) 2018-03-20 US disclosed
US-9919299-B2 Metathesis catalysts and reactions using the catalysts XIMO AG (CH) 2018-03-20 US disclosed
US-20180065914-A1 RUTHENIUM POLYMERISATION CATALYSTS UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2018-03-08 US disclosed
US-9815765-B2 Ruthenium polymerisation catalysts UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) 2017-11-14 US disclosed
US-9776178-B2 Ruthenium complexes comprising an asymmetrical unsaturated N-heterocyclic diaminocarbene ECOLE NATIONALE SUPERIEURE DE CHIMIE DE RENNES (FR) 2017-10-03 US disclosed
US-9718849-B2 Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) 2017-08-01 US disclosed
US-8398931-B2 Recirculating reactor AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2013-03-19 US disclosed
US-20130030209-A1 PHOSPHINATE RUTHENIUM COMPLEXES IDENIX PHARMACEUTICALS, INC. (US) 2013-01-31 US disclosed
US-8309737-B2 Phosphinate ruthenium complexes IDENIX PHARMACEUTICALS, INC. (US) 2012-11-13 US disclosed
US-20120082847-A1 RADIATION CURABLE POLY(ISOBUTYLENE) ADHESIVE COPOLYMERS 3M INNOVATIVE PROPERTIES COMPANY 2012-04-05 US disclosed
US-20120041191-A1 PHOSPHINATE RUTHENIUM COMPLEXES IDENIX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20110124868-A1 RUTHENIUM OLEFIN METATHESIS CATALYSTS BEARING N-HETEROCYCLIC CARBENE LIGANDS WITH SUBSTITUTED BACKBONE MATERIA, INC. (US) 2011-05-26 US disclosed
US-20110040099-A1 METHOD FOR MANUFACTURING RUTHENIUM CARBENE COMPLEXES EVONIK DEGUSSA GMBH (DE) 2011-02-17 US disclosed
US-20110015402-A1 RECIRCULATING REACTOR AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2011-01-20 US disclosed
US-20110009621-A1 SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS Raap Polymere GmbH (DE) 2011-01-13 US disclosed
US-20100173863-A1 2-Fluoronucleosides NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009621-A1 SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS SCO2, SOD1, PPIF CYP4F2 146/4885CYP4A11 989/4885PKM 1053/4885
US-20110040099-A1 METHOD FOR MANUFACTURING RUTHENIUM CARBENE COMPLEXES RNF168, CROCC, MRPL21 CYP4F2 217/4885CYP4A11 314/4885PKM 2550/4885
US-20100173863-A1 2-Fluoronucleosides PNP, BCL3, NPC1 CYP4F2 748/4885CYP4A11 782/4885PKM 3976/4885
US-20110015402-A1 RECIRCULATING REACTOR DCXR, POR, CTRC CYP4F2 122/4885CYP4A11 56/4885PKM 1172/4885
US-20180065914-A1 RUTHENIUM POLYMERISATION CATALYSTS RRP12, PCBP1, PARG CYP4F2 1707/4885CYP4A11 3716/4885PKM 273/4885
US-11794179-B2 Synthesis and characterization of metathesis catalysts SQLE, FDFT1, FASN CYP4F2 60/4885CYP4A11 90/4885PKM 1626/4885
US-11779912-B2 Synthesis and characterization of Ru alkylidene complexes PORCN, ORC3, COASY CYP4F2 120/4885CYP4A11 824/4885PKM 2447/4885
US-20120041191-A1 PHOSPHINATE RUTHENIUM COMPLEXES RPIA, NDUFS7, PHOSPHO1 CYP4F2 666/4885CYP4A11 2768/4885PKM 1631/4885
US-20110124868-A1 RUTHENIUM OLEFIN METATHESIS CATALYSTS BEARING N-HETEROCYCLIC CARBENE LIGANDS WITH SUBSTITUTED BACKBONE NUDC, TEC, ORC3 CYP4F2 839/4885CYP4A11 3002/4885PKM 3971/4885
US-20130030209-A1 PHOSPHINATE RUTHENIUM COMPLEXES RPIA, NDUFS7, POP1 CYP4F2 594/4885CYP4A11 2384/4885PKM 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.